[go: up one dir, main page]

CA2511174A1 - Oligosaccharides et conjugues pour le traitement d'infections par bacterie pseudomonale - Google Patents

Oligosaccharides et conjugues pour le traitement d'infections par bacterie pseudomonale Download PDF

Info

Publication number
CA2511174A1
CA2511174A1 CA002511174A CA2511174A CA2511174A1 CA 2511174 A1 CA2511174 A1 CA 2511174A1 CA 002511174 A CA002511174 A CA 002511174A CA 2511174 A CA2511174 A CA 2511174A CA 2511174 A1 CA2511174 A1 CA 2511174A1
Authority
CA
Canada
Prior art keywords
compound
bacteria
pseudomonas
solution
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002511174A
Other languages
English (en)
Inventor
John L. Magnani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crescent Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2511174A1 publication Critical patent/CA2511174A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des méthodes en rapport avec la bactérie pseudomonale. Ces compositions et méthodes peuvent s'utiliser pour le diagnostic et le traitement d'états impliquant une infection par la bactérie pseudomonale. De telles infections peuvent être provoquées par Pseudomonas aeruginosa dans les poumons de patients souffrant de mucoviscidose. Un composé de l'invention peut être couplé à un agent thérapeutique. Pour inhiber les bactéries pseudomonales, on peut en bloquer la colonisation, en stopper la croissance ou les tuer.
CA002511174A 2002-12-20 2003-12-19 Oligosaccharides et conjugues pour le traitement d'infections par bacterie pseudomonale Abandoned CA2511174A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43595802P 2002-12-20 2002-12-20
US60/435,958 2002-12-20
PCT/US2003/040881 WO2004058304A1 (fr) 2002-12-20 2003-12-19 Oligosaccharides et conjugues pour le traitement d'infections par bacterie pseudomonale

Publications (1)

Publication Number Publication Date
CA2511174A1 true CA2511174A1 (fr) 2004-07-15

Family

ID=32682307

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002511174A Abandoned CA2511174A1 (fr) 2002-12-20 2003-12-19 Oligosaccharides et conjugues pour le traitement d'infections par bacterie pseudomonale

Country Status (5)

Country Link
EP (1) EP1575619A1 (fr)
JP (1) JP2006515306A (fr)
AU (1) AU2003301209A1 (fr)
CA (1) CA2511174A1 (fr)
WO (1) WO2004058304A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE383367T1 (de) * 2003-11-19 2008-01-15 Glycomimetics Inc Spezifischer antagonist sowohl für e- als auch p- selektine
US20050187171A1 (en) * 2003-11-19 2005-08-25 Glycomimetics, Inc. Glycomimetic antagonists for both E-and P-selectins
ATE528311T1 (de) * 2005-08-09 2011-10-15 Glycomimetics Inc Glycomimetische inhibitoren des pa-il-lectins, pa-iil-lectins oder beider lectine aus pseudomonas
SI1934236T1 (sl) * 2005-09-02 2013-02-28 Glycomimetics, Inc. Heterobifunkcionalni inhibitorji pan-selektina
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
KR102055958B1 (ko) 2011-12-22 2019-12-13 글리코미메틱스, 인크. E-셀렉틴 길항제 화합물, 조성물, 및 이용 방법
CA2891514C (fr) 2012-12-07 2020-08-25 Glycomimetics, Inc. Composes, compositions et procedes utilisant des antagonistes d'e-selectine pour la mobilisation de cellules hematopoietiques
PT3227310T (pt) 2014-12-03 2019-11-06 Glycomimetics Inc Inibidores heterobifuncionais de e-selectinas e recetores de quimiocina cxcr4
WO2017095904A1 (fr) * 2015-12-02 2017-06-08 Glycomimetics, Inc. Antagonistes hétérobifonctionnels de pan-sélectine présentant un lieur de type triazole
CA3009836A1 (fr) 2016-01-22 2017-07-27 Glycomimetics, Inc. Inhibiteurs glycomimetiques des lectines pa-il et pa-iil
WO2017151708A1 (fr) 2016-03-02 2017-09-08 Glycomimetics, Inc. Méthodes pour le traitement et/ou à la prévention de maladies cardiovasculaires par inhibition de la sélectine e
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CN109890421B (zh) 2016-10-07 2023-10-20 糖模拟物有限公司 高效的多聚体e-选择蛋白拮抗剂
CA3054605A1 (fr) 2017-03-15 2018-09-20 Glycomimetics, Inc. Derives de galactopyranosyle-cyclohexyle utilises en tant qu'antagonistes d'e-selectine
JP7275131B2 (ja) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2019173229A1 (fr) 2018-03-05 2019-09-12 Glycomimetics, Inc. Méthodes de traitement de la leucémie aiguë myéloïde et d'états pathologiques associés
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028174A1 (fr) * 1996-01-30 1997-08-07 Novartis Ag Analogues d'epitopes de sialyle-lewisa et de sialyle-lewis?x¿
US6169077B1 (en) * 1996-01-30 2001-01-02 Glycotech Corp. Sialyl-Lewisa and sialyl-Lewisx epitope analogues
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU8967998A (en) * 1998-02-25 1999-09-15 Hsc Research & Development Limited Partnership Antibiotic-ligand conjugates and methods of use thereof
AU2003249641B2 (en) * 2002-05-16 2009-08-20 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function

Also Published As

Publication number Publication date
JP2006515306A (ja) 2006-05-25
WO2004058304A1 (fr) 2004-07-15
AU2003301209A1 (en) 2004-07-22
EP1575619A1 (fr) 2005-09-21

Similar Documents

Publication Publication Date Title
CA2511174A1 (fr) Oligosaccharides et conjugues pour le traitement d'infections par bacterie pseudomonale
US20040219158A1 (en) Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US8258290B2 (en) Glycomimetic inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from pseudomonas
US7230096B2 (en) Inhibitors against galectins
US8530448B2 (en) Compounds and methods for inhibiting selectin-mediated function
US8703720B2 (en) Galactoside inhibitors of galectins
US7361644B2 (en) Specific antagonist for both E- and P-selectins
US20050187171A1 (en) Glycomimetic antagonists for both E-and P-selectins
US6110897A (en) Antiinflammatory cell adhesion inhibitors
US6503885B1 (en) Carboxymethylgalactose derivatives
US20090176717A1 (en) Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
AU6513094A (en) Novel sphingoglycolipid and use thereof
DE4436164A1 (de) Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US20040096396A1 (en) Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
JPH08512026A (ja) 細菌接着阻害剤としてのフコシル化グリコシド
WO2000056343A1 (fr) Structures glucidiques de n-acetyl lactosamine fucosyle sialyle permettant d'inhiber l'adhesion bacterienne
EP0731704A4 (fr) Glycosamines de synthese favorisant ou inhibant l'adherence cellulaire
WO1994011005A1 (fr) Inhibiteurs de fixation virale
Pogosyan Efficient synthesis of building blocks for the preparation of pectin fragments by modular design principle

Legal Events

Date Code Title Description
FZDE Dead